What We Do Not Offer, and Why
Most clinics publish a list of what they provide. This is the other list, and for a patient weighing up a longevity programme it is the more useful one.
Most clinics publish a list of what they offer. This page is the other list, and it is the more useful one.
We do not provide stem cell therapy. We do not provide NAD+ infusions. We do not provide treatments that are not registered for the purpose they are being sold for.
That is not a gap in our service. It is a decision, and I want to set out the reasoning plainly, because a patient deserves to know what a clinic will not do before they sit down, not after.
Key takeaways
- Malaysia's NPRA guidance excludes general well-being, cosmetic or aesthetic purposes and rejuvenation as permitted purposes for cell and gene therapy products, unless there is a medicinal purpose supported by clinical studies.
- Those are precisely the purposes these treatments are marketed for here.
- The Malaysia Healthcare Travel Council states that NPRA has not approved or registered any stem cell or cell-based therapy as a standard medicine.
- NAD+ biology is genuinely interesting. No trial shows that infusing it extends healthy lifespan, improves function or reduces disease in people who are not deficient.
- Patient demand is not a clinical justification. It only changes whether declining costs us money.
- What replaces it is unglamorous: assessment, selective measurement, interpretation by a doctor, and interventions with outcome evidence.
Why we decline these
The regulator has not approved them for this purpose
This is the part most patients are never told.
Malaysia's National Pharmaceutical Regulatory Agency publishes guidelines for the registration of cell and gene therapy products. The current second edition, issued in September 2025 under Regulation 29 of the Control of Drugs and Cosmetics Regulations 1984, states that these products are not allowed for general well-being, cosmetic or aesthetic purposes, or rejuvenation, unless they are intended for a medicinal purpose and supported by clinical studies.
Read that against how these treatments are actually marketed here. Anti-ageing. Cellular rejuvenation. Wellness optimisation. Those are precisely the purposes the guideline excludes.
The Malaysia Healthcare Travel Council, which is the government's own agency, states separately and publicly that NPRA has not approved or registered any stem cell or cell-based therapy as a standard medicine, and warns that serious complications have most often been linked to unregulated providers and exaggerated claims.
So when a clinic tells you that what they are offering is legal, approved and safe, there is a specific question worth asking, and our guide to checking whether a provider or treatment is registered sets out how to ask it.
The evidence does not support what is claimed for them
Take NAD+ as the clearest example, because the underlying science is genuinely interesting and the clinical offering is not.
NAD+ metabolism matters. It is involved in cellular energy production and in the function of several enzyme systems that are relevant to ageing biology. Declining NAD+ with age is a real research finding, and I follow the field.
None of that establishes that infusing it produces a longevity benefit in a healthy adult. The studies that exist are small, mostly short, and measure biochemical markers rather than health outcomes. There is no trial showing that NAD+ infusion extends healthy lifespan, improves function, or reduces disease in people who are not deficient.
What there is, in abundance, is a price list.
The same pattern repeats across the category. A mechanism that is real, a product that has not been shown to act on it usefully, and a claim that sits far ahead of both.
Demand is not a clinical justification
Patients ask us for these treatments. Often, and sometimes insistently, having read about them or having been offered them elsewhere.
That is not a reason to provide them. If a treatment cannot be justified on evidence and is not approved for the purpose, the fact that someone wants it and will pay for it does not change either of those things. It only changes whether declining costs us money.
What we do instead
The honest answer is that it is less exciting and it works better.
Assessment. A history and an examination, which is where most of the useful information in medicine still comes from, and which no panel replaces.
Measurement, selected for the person. A small number of tests chosen because the result would change a decision, rather than a large panel chosen because it looks thorough. If we cannot tell you what we would do differently depending on the result, we should not be ordering it.
Interpretation. Somebody reading your results with you, in the context of your history, and telling you what they mean and what they do not. A result with nobody interpreting it is not screening.
Interventions with outcome evidence. Physical activity and resistance training. Sleep. Nutrition. Body composition and visceral fat. Managing the cardiovascular and metabolic risks that actually shorten lives. Appropriate preventive care and vaccination. Where medication is indicated, prescribed and monitored properly by a registered medical practitioner.
Follow-up that measures whether anything changed. Which is the part most longevity offerings skip, because it is where claims get tested.
None of that photographs well. It is what the evidence supports. Our article on the assessment pathway sets out what that looks like in practice.
What this means for you, practically
You may be told no. If you come to us wanting a specific treatment from the list above, we will explain why we do not provide it, and we will not offer you a substitute simply to have something to sell. You are free to go elsewhere for it, and some patients do. That is a reasonable outcome and we would rather it happen at the first consultation than later.
You may be told to do less. A fair number of consultations end with a shorter plan than the patient expected, and occasionally with nothing other than a recommendation and a review date.
You may be sent somewhere else. Not every problem belongs in a longevity programme. Where something needs a specialist, imaging or a tertiary centre, that is where it should go.
We will tell you what we do not know. Where the evidence is thin, we say so. Where a test is a research tool rather than a diagnosis, we say that too.
A note on how we are structured
Hayat Longevity is a longevity programme. Clinical services are delivered by registered medical practitioners at AOKLINIK Penang, a licensed medical clinic operating under Malaysian healthcare regulation.
That distinction matters for exactly the reasons this page is about. Medical treatment should be given in a licensed medical facility by a registered practitioner, with the governance and accountability that comes with both. A wellness brand administering treatments outside that framework is the structural problem behind most of what goes wrong in this field.
The short version
We do not offer stem cell therapy, NAD+ infusions, or other treatments that are not registered for the purpose they are sold for.
The regulator has specifically excluded rejuvenation and general well-being as permitted purposes for cell and gene therapy products unless there is a medicinal purpose and clinical evidence. The evidence behind these treatments does not support what is claimed for them. And patient demand does not make an unjustifiable treatment justifiable.
What we do instead is assessment, selective measurement, interpretation by a doctor, and interventions that have outcome evidence behind them.
If you want a clinic that will say yes to everything, we are not it, and you will have no difficulty finding one.
If you are weighing up a treatment you have been offered somewhere else, bring the details. We will tell you what the evidence shows and what the regulatory position is, whether or not it is something we provide. The pre-consultation questionnaire is the place to start.
Frequently asked questions
Does Hayat Longevity offer stem cell therapy?
No. Malaysia's NPRA guidance for cell and gene therapy products excludes general well-being, cosmetic or aesthetic purposes and rejuvenation as permitted purposes, unless the product is intended for a medicinal purpose and supported by clinical studies. The Malaysia Healthcare Travel Council states that NPRA has not approved or registered any stem cell or cell-based therapy as a standard medicine.
Why do you not offer NAD+ infusions?
Because the evidence does not support what is claimed for them. NAD+ metabolism is genuinely relevant to ageing biology, and declining NAD+ with age is a real research finding. But the studies on infusion are small, mostly short, and measure biochemical markers rather than health outcomes. No trial shows it extends healthy lifespan, improves function or reduces disease in people who are not deficient.
What if I want the treatment anyway?
We will explain why we do not provide it and will not offer a substitute simply to have something to sell. You are free to go elsewhere, and some patients do. We would rather that conversation happened at the first consultation than afterwards.
What does a longevity programme consist of if not these treatments?
Assessment through history and examination, a small number of tests chosen because the result would change a decision, interpretation of those results by a doctor in the context of your history, interventions with outcome evidence behind them, and follow-up that measures whether anything actually changed.
How do I check whether something I have been offered elsewhere is legitimate?
Four separate frameworks govern the practitioner, the premises, the product and the device, and a provider can satisfy one while failing another. Our guide to verifying a provider in Malaysia sets out what each check proves and, more usefully, what each one does not. Written by Dr. Daniel Chong, Human Performance and Longevity. AOKLINIK Penang. General information only and not individual medical advice. Regulatory guidelines are revised periodically and the position described reflects the guidance in force at the date of publication.
References
- NPRA. Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products in Malaysia, 2nd edition, September 2025.
- Malaysia Healthcare Travel Council. Stem cell therapy in Malaysia: separating fact from hype.
- Control of Drugs and Cosmetics Regulations 1984, Regulation 29.
